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1. Pap test screening:	Routine	screening	by	conventional	Pap	test	in	women	who	have	ever	been	sexually	active	and	have	no	symptoms	or	
history	suggestive	of	cervical	pathology.
2. hPv dnA test screening:	Routine	screening	by	HPV	DNA	test	(Hybrid	Capture	II)	in	women	who	have	ever	been	sexually	active	and	have	
no	symptoms	or	history	suggestive	of	cervical	pathology.
3. Combined Pap test and hPv dnA test screening: Routine	screening	by	a	combination	of	conventional	Pap	test	and	HPV	DNA	test	
(positive	on	either	test	will	be	referred	for	further	investigation)	in	women	who	have	ever	been	sexually	active	and	have	no	symptoms	or	
history	suggestive	of	cervical	pathology.
4. hPv vaccination and Pap test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV1	vaccine	and	continue	screening	with	Pap	test.
5. hPv vaccination and hPv dnA test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV	vaccine	and	continue	screening	with	HPV	DNA	
test.
6. hPv vaccination and combined Pap and hPv dnA test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV	vaccine	and	continue	
screening	with	combined	Pap	and	HPV	DNA	test.
7. sunsmart program2  for skin cancer prevention:	An	on-going	national	SunSmart	program	with	increased	investment	at	$0.28	per	capita	
for	the	next	20	years.	
8. screening for prostate cancer:	a	one-off	screening	test	for	prostate	specific	antigen	(PSA)	in	the	male	population	aged	55-70	in	2003.	
Comparator	is	no	screening.
9. trastuzumab (herceptintm) treatment for breast cancer:	adjuvant	trastuzumab	and	chemotherapy	(ATC)	for	all	newly	diagnosed	breast	
cancer	aged	30-100	with	positive	human	epidermal	growth	factor	receptor	2	(HER2)	in	2003.	Comparator	is	no	trastuzumab.






























Intervention DALY averted Incremental  
net cost ($m)
ICER $/DALY
base case3  (ranges)
Pap test screening
A. Pap screen every 2 year from age 25 -100 -15.1 health loss with less cost
152,000^
B. Pap screen every 3 year from age 18 -393 -29.2 health loss with less cost
74,000^
HPV DNA test screening
C. HPV DNA test screen every 3 year from age 18 59 0.6 11,000
Combined Pap and HPV DNA test screening
D. Combined Pap screen and HPV DNA test screen 
every 3 year from age 18
190 16.0 84,000
E. Pap screen for age 18-29 and combined screen 
from age 30 every 3 year
84 -1.4 Dominant*
F. Combined screen every 3 year from age 25 156 -1.9 Dominant*
HPV vaccination and Pap test  screening
G. HPV vaccination at age 12 and Pap screen every 
2 year from age 18
786 35.9 46,000   
(40,000 - 55,000)
H. HPV vaccination at age 12 and Pap  screen every 
2 year from age 25
765 20.8 27,000   
(23,000 – 34,000)
I. HPV vaccination at age 12 and Pap screen every 
3 year from age 18
679 8.5 12,000   
(10,000 – 18,000)
HPV vaccination and HPV DNA test screening
J. HPV vaccination at age 12 and HPV DNA test 
screen every 3 year from age 18
828 33.9 41,000   
(36,000 - 49,000)
HPV vaccination and combined Pap &  
HPV DNA test screening
K. HPV vaccination at age 12 and combined Pap & 
HPV DNA test screen every 3 year from age 18
878 49.3 56,000   
(51,000 – 65,000)
L. HPV vaccination at age 12 and Pap screen for 
age 18-29 and combined screen from age 30 
every 3 year
857 33.7 39,000   
(35,000 – 46,000)
M. HPV vaccination at age 12 and combined Pap & 
HPV DNA test screen every 3 year from age 25
873 32.9 38,000   
(34,000 – 44,000)
SunSmart program for skin cancer prevention #
N. SunSmart program for 20 years 120,000 2,000 16,000  
(12,000 – 22,000)
Screening for prostate cancer
O. One-off screening for males 55-70 in 2003 -3,400 Not calculated Health loss with  
higher costs
Trastuzumab treatment for breast cancer #
P. Adding trastuzumab (HerceptinTM) to standard 
chemotherapy for all newly diagnosed breast 
cancer with positive human epidermal growth 
factor receptor 2















































14. Renal replacement therapy, screening and early  
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methods: 
A.			The	ACE-Prevention	project	
B.			ACE	approach	to	priority	setting	
C.			Key	assumptions	underlying	the	economic	analysis	
D.			Interpretation	of	ACE-Prevention	cost-effectiveness	results	
E.			Indigenous	Health	Service	Delivery	
